|
業務類別
|
Biotechnology |
|
業務概覽
|
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes an array of oncology and dermatology programs. |
| 公司地址
| 1801 Augustine Cut-Off, Wilmington, DE, USA, 19803 |
| 電話號碼
| +1 302 498-6700 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.incyte.com |
| 員工數量
| 2844 |
| Dr. Pablo J. Cagnoni, M.D. |
President and Global Head, Research and Development |
美元 966.52K |
26/03/2026 |
| Mr. William J. Meury |
Director and Chief Executive Officer |
美元 647.26K |
26/03/2026 |
| Dr. Steven H. Stein, M.D. |
Executive Vice President, Chief Medical Officer and Head, Late-stage Development |
美元 835.07K |
26/03/2026 |
| Mr. Michael James Morrissey |
Executive Vice President and Head of Global Technical Operations |
-- |
10/02/2026 |
| Mr. Thomas Tray |
Principal Financial Officer, Vice President and Chief Accounting Officer |
美元 358.19K |
10/02/2026 |
| Mr. Matteo Trotta |
Executive Vice President and General Manager, Dermatology US |
-- |
10/02/2026 |
| Mr. Lee Heeson |
Executive Vice President, Incyte International |
-- |
10/02/2026 |
| Mr. Mohamed Khairie Issa |
Executive Vice President and Head, U.S. Commercial |
美元 690.41K |
26/03/2026 |
| Mr. David H. Gardner |
Executive Vice President and Chief Strategy Officer |
-- |
10/02/2026 |
| Mr. Richard A. Hoffman |
Executive Vice President and General Counsel |
-- |
10/02/2026 |
| Ms. Soni Basi |
Executive Vice President and Chief Human Resources Officer |
-- |
10/02/2026 |
|
|
| Mr. Jean-Jacques Bienaime |
Independent Director |
28/04/2026 |
| Mr. Julian C. Baker |
Chairman of the Board |
28/04/2026 |
| Mr. Paul J. Clancy, M.B.A. |
Independent Director |
28/04/2026 |
| Dr. Jacqualyn A. Fouse, PhD |
Independent Director |
28/04/2026 |
| Dr. Otis W. Brawley,M.D. |
Independent Director |
28/04/2026 |
| Mr. William J. Meury |
Director and Chief Executive Officer |
26/03/2026 |
| Dr. Edmund P. Harrigan, M.D. |
Independent Director |
28/04/2026 |
| Dr. Katherine A. High, M.D. |
Independent Director |
28/04/2026 |
|
|
|
|
